NEWS & EVENTS

Latest news and upcoming events

SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline
16 Feb 2022

SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline

Upcoming events
  • ESMO Congress
    9 – 13 September 2022,
    Paris

    download
  • 22nd Annual Biotech in Europe Forum
    21 - 22 September, 2022
    Basel

    download
  • Brain Innovation Days
    11 – 12 October 2022,
    Brussels

    download
Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting<

Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting

These data show that AU-011, a first in class VDC, in combination with immune checkpoint inhibition is effective against both primary tumors and distant metastases in a preclinical model

Aura Biosciences to Participate in Upcoming Investor Conferences<

Aura Biosciences to Participate in Upcoming Investor Conferences

Webcast of the Cowen fireside chat and Jefferies presentation will be available on Aura's “Investors & Media” page

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.<

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

Kala Will Receive $60 Million in Upfront Payment; Eligible to Receive Additional Sales-Based Milestone Payments

SparingVision Presents Additional Data on its Breakthrough Gene Therapy Approach SPVN06 at ASGCT 2022<

SparingVision Presents Additional Data on its Breakthrough Gene Therapy Approach SPVN06 at ASGCT 2022

Findings provide additional preclinical validation ahead of IND/CTA submission planned in Q3 2022

LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results<

LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results

• LAVA-1207 Phase 1/2a trial in metastatic castration-resistant prostate cancer dosed the first patients and is on track to report initial data in H2 2022

Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights<

Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

We continue to advance the AU-011 overall development program and look forward to several upcoming clinical milestones, in the second half of this year

LAVA Therapeutics Announces FDA IND Clearance for LAVA-051 for the Treatment of Hematologic Malignancies<

LAVA Therapeutics Announces FDA IND Clearance for LAVA-051 for the Treatment of Hematologic Malignancies

Supported by encouraging preclinical and preliminary clinical data, we believe in the potential of LAVA-051 to address unmet patient needs.

CVRx® Receives MR-Conditional Labeling Approval for its Barostim™ Heart Failure System<

CVRx® Receives MR-Conditional Labeling Approval for its Barostim™ Heart Failure System

Heart failure patients implanted with Barostim can now receive conditional MRI scans

LAVA Therapeutics to Participate at the UBS Global Healthcare Conference<

LAVA Therapeutics to Participate at the UBS Global Healthcare Conference

Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer

SparingVision Presents Progress of its Lead Gene Therapy Program, SPVN06, at ARVO 2022<

SparingVision Presents Progress of its Lead Gene Therapy Program, SPVN06, at ARVO 2022

demonstrating a highly significant protection of visual function as well as greater cone density following subretinal administration of SPVN06 in a murine model.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.